CLINICAL_TRIALS
trial_result
· 2020-10-27
Clinical Trial Update: A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma [Phase 2]
Summary
Phase 2 biomarker study of tivozanib in advanced renal cell carcinoma has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: AVEO Pharmaceuticals, Inc. | Conditions: Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-10-27